Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Dorothea Wagner

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
ESMO Open|September 24, 2020
Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapyAnna Dorothea Wagner
Cancers|February 25, 2022
(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex DifferencesThomas Zander, Anna Dorothea Wagner
Drugs & Aging|August 19, 2009
Advances in the pharmacological treatment of gastro-oesophageal cancerAnna Dorothea Wagner, Ulrich Wedding
World Journal of Gastroenterology|March 4, 2016
Advanced gastric cancer: Current treatment landscape and future perspectivesAntonia Digklia, Anna Dorothea Wagner
JAMA Oncology|December 14, 2018
Inappropriate Grading of Adverse Events in Cancer Clinical Trials-ReplyValerie Cristina, Murielle Mauer, Anna Dorothea Wagner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2018
Reply to L. Pala et alAnna Dorothea Wagner, Berna Özdemir, Chantal Csajka
The Cochrane Database of Systematic Reviews|July 13, 2012
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancerAnna Dorothea Wagner, Christoph Thomssen, Johannes Haerting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2018
Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision OncologyBerna C Özdemir, Chantal Csajka, Gian-Paolo Dotto, et al.
Oncology Research and Treatment|March 9, 2020
Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in SwitzerlandAlexander Siebenhüner, Sara De Dosso, Alexander Meisel, et al.
Revue Medicale Suisse|May 15, 2025
[Recent advances in immunotherapy for gastrointestinal tumors]Christophe Cisarovsky, Giovanni Dei Tos, Nils Degrauwe, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
ESMO Open|September 24, 2020
Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapyAnna Dorothea Wagner
Cancers|February 25, 2022
(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex DifferencesThomas Zander, Anna Dorothea Wagner
Drugs & Aging|August 19, 2009
Advances in the pharmacological treatment of gastro-oesophageal cancerAnna Dorothea Wagner, Ulrich Wedding
World Journal of Gastroenterology|March 4, 2016
Advanced gastric cancer: Current treatment landscape and future perspectivesAntonia Digklia, Anna Dorothea Wagner
JAMA Oncology|December 14, 2018
Inappropriate Grading of Adverse Events in Cancer Clinical Trials-ReplyValerie Cristina, Murielle Mauer, Anna Dorothea Wagner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2018
Reply to L. Pala et alAnna Dorothea Wagner, Berna Özdemir, Chantal Csajka
The Cochrane Database of Systematic Reviews|July 13, 2012
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancerAnna Dorothea Wagner, Christoph Thomssen, Johannes Haerting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2018
Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision OncologyBerna C Özdemir, Chantal Csajka, Gian-Paolo Dotto, et al.
Oncology Research and Treatment|March 9, 2020
Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in SwitzerlandAlexander Siebenhüner, Sara De Dosso, Alexander Meisel, et al.
Revue Medicale Suisse|May 15, 2025
[Recent advances in immunotherapy for gastrointestinal tumors]Christophe Cisarovsky, Giovanni Dei Tos, Nils Degrauwe, et al.
Pageof 5